Elise Biopharma’s Albumin-Fusion Protein Platform harnesses the intrinsic pharmacokinetic superpower of human serum albumin to convert short-lived payloads into long-acting biologics. By engineering Albumin-Fusion Proteins—either via direct genetic fusion to HSA or through high-affinity albumin-binding domains—we leverage FcRn-mediated recycling, pH-dependent endosomal salvage, and albumin’s large hydrodynamic radius to delay renal filtration and endosomal degradation. The result is weeks-scale exposure from payloads that would otherwise clear in hours. Our program is built on a tight QbD framework: rational domain architecture (linker chemistry, orientation, and protease-cleavable options), host selection for manufacturability (CHO, HEK, or Pichia glyco-variants), and stage-gated analytics (PK/PD modeling, FcRn binding kinetics, stability and aggregation risk) that align with IND/BLA expectations. End-to-end, we design, express, purify, and characterize Albumin-Fusion Proteins with transfer-ready processes, validated release methods, and comparability packages that scale cleanly from discovery to GMP.
Where typical conjugates fight batch heterogeneity, Albumin-Fusion Proteins are genetically precise: a single primary sequence defines the drug. We optimize codons and secretion signals for high titers, select linkers to balance flexibility with protease resistance, and use orthogonal assays—HPLC-SEC/MALS, DSC/DLS, CE-SDS, LC-MS peptide mapping—to de-risk developability. On the PK side, we quantify FcRn interaction (pH 6.0 on-rate / pH 7.4 off-rate) to tune exposure, then simulate dose intervals using non-linear mixed-effects models. Downstream, capture/polish trains are tailored for albumin’s surface chemistry (AEX/HIC or mixed-mode) to preserve activity and minimize host-cell impurities. All data flows into a CMC narrative with CPP→CQA maps, ensuring a straight line from design choices to clinical performance.
Why Albumin Fusion?
Prolonged Half-Life
Albumin engages the neonatal Fc receptor (FcRn) in endosomes, is recycled to plasma, and avoids lysosomal degradation. When fused or tightly bound, your payload hitchhikes on that salvage pathway, extending effective half-life from hours to many days—often enabling q1–4 week dosing.
Reduced Dosing Frequency
Higher exposure and slower clearance translate into fewer injections and steadier troughs. For chronic indications (human or veterinary), this improves adherence and can reduce clinic visits, ancillary supplies, and total cost of care.
Enhanced Stability
The albumin domain shields protease sites and increases hydrodynamic size, reducing renal filtration and aggregation propensity. We validate with forced-degradation panels (heat, pH, agitation, oxidants) and correlate to real-time/accelerated ICH stability to support shelf-life claims.
Targeted Delivery (Passive Accumulation)
Albumin naturally partitions into inflamed and tumor microenvironments via enhanced permeability and retention (EPR) and albumin-transport mechanisms. Fusions exploit this passive targeting while maintaining systemic exposure profiles tuned by FcRn kinetics.
Bottom line: For long-acting cytokines, growth factors, enzymes, and peptide therapeutics, Albumin-Fusion Proteins offer a genetically defined, scalable route to sustained exposure, simpler regimens, and regulator-friendly CMC.
Our Albumin‑Fusion Engineering Workflow
A. Design & In Silico Modeling
- Fusion Orientation: N‑ vs C‑terminal attachment to preserve both payload activity and albumin function.
- Linker Selection: Rigid, flexible, or protease‑cleavable linkers tuned for optimal expression and biological release.
- Computational Prediction: Molecular dynamics and docking simulations assess FcRn binding, steric compatibility, and aggregation risks.
B. Genetic Construct & Codon Optimization
- Gene Synthesis: Codon‑optimized cassettes for CHO, HEK, or microbial hosts.
- Vector Design: Single‑ or dual‑promoter systems to balance payload and albumin expression.
C. Expression Host Selection
- Mammalian Cells: CHO or HEK for fully human‑like glycosylation patterns.
- Microbial Systems: Engineered Pichia pastoris for rapid, cost‑effective production of smaller fusions or albumin‑binding domains.
Process Development & Scale‑Up
Upstream Optimization
- Fed‑Batch & Perfusion: Media and feed strategies to maximize titer (>2 g/L typical).
- Bioreactor Scales: From 2 L discovery runs to 2 000 L GMP production.
Downstream Purification
- Affinity Capture: Protein A/G or albumin‑binding resin for high selectivity.
- Polishing Steps: Ion‑exchange and hydrophobic‑interaction chromatography to remove host impurities.
- Viral Clearance: Low‑pH inactivation and nanofiltration for mammalian systems.
Analytical Characterization
- SPR/BLI: FcRn binding kinetics to confirm recycling potential.
- SEC‑MALS & DLS: Determine monomeric purity and aggregation profiles.
- DSC/DSF: Assess thermal stability improvements conferred by albumin fusion.
Pharmacokinetics & Bioanalysis
- In Vivo PK Studies: Rodent and non‑rodent models to quantify half‑life extension (often 3–10× increase).
- Bioanalytical Assays: LC‑MS/MS and ligand‑binding assays for accurate quantification in serum.
- PD Biomarkers: Functional readouts (e.g., sustained cytokine signaling, growth factor activity).
These data drive dose‑finding, IND/IMPD submissions, and clinical/trial design.
Formulation & Delivery
- Liquid Formulations: Buffers optimized for albumin stability and solubility.
- Lyophilized Presentations: Freeze‑dry cycles developed under QbD to ensure rapid reconstitution without loss of activity.
- Combination Products: Dual‑chamber cartridges separating diluent and lyophilizate for on‑demand preparation.
Our fill/finish suites support vials, pre‑filled syringes, and cartridges under aseptic conditions.
Conclusion: Regulatory & CMC Support that de-risks launch
Choosing an Albumin Fusion Protein CDMO early pays compounding dividends: you align clinical strategy with manufacturability, lock a control strategy that survives scale-up, and avoid “late learnings” that stall filings. As your Albumin Fusion Protein CDMO, we don’t just make drug substance—we author the story regulators need to read, with data that map mechanism → quality → patient benefit.
CMC & Regulatory Deliverables
- eCTD-ready CMC modules (2.3/3.2): fusion construct rationale (linker chemistry, domain order, FcRn engagement), upstream/downstream process descriptions, batch records, and full analytical validation reports (potency, identity, purity, glycan/charge variants, binding).
- Control strategy & QbD: QTPP→CQA mapping (half-life, FcRn affinity, isoform distribution, aggregates), CPP envelopes (feed profile, pH/Temp holds, shear budgets), DoE summaries, proven acceptable ranges, and PPQ/CPV plans.
- Immunogenicity & safety risk assessments: FcRn-related exposure modeling, neo-epitope in-silico screens, HCP profiling, residuals, and excipient qualification; risk register with mitigations and acceptance criteria.
- Comparability & bridging (ICH Q5E): statistically powered studies to bridge payload-only biologics to albumin-fusion formats (potency, binding kinetics, ADCC/CDC as applicable, PK/PD).
- Stability & forced degradation: thermal/oxidation/deamidation stress, aggregation kinetics by SEC-MALS, charge variants (icIEF), peptide mapping, and shelf-life modeling to justify retest intervals and label storage.
- Global pathways: FDA/EMA/VMD alignment, veterinary vs. human routes, regional pharmacopeia testing, and briefing packages for scientific advice. As an Albumin Fusion Protein CDMO, we harmonize CMC language across agencies to minimize review churn.
Case Study — Canine IL-10–Albumin Fusion (Arthritis)
Objective: Extend IL-10 exposure to reduce dosing frequency while maintaining anti-inflammatory potency in canines.
Design: Canine IL-10 fused N-terminally to albumin via flexible (G₄S)₃ linker; secretion signal optimized; CHO expression with QbD media/titer DoE; FcRn binding tuned to the target species.
Process: Scalable capture (affinity/ion-exchange), polish to ≤1% HMW by SEC, low endotoxin via single-use flow path; tech-transfer pack included PARs and resin lifetime studies.
Analytics: Cell-based anti-TNF surrogate assay, IL-10 receptor binding (SPR), FcRn affinity at pH 6.0/7.4, icIEF charge heterogeneity, glycan profiling, LC–MS peptide map integrity.
Results:
- 8-fold half-life extension in canine PK with preserved potency.
- 70% reduction in joint swelling after a single dose (pilot clinical).
- 200 L cGMP manufacture, >95% purity, <1% aggregates, CoA reproducibility across three engineering + PPQ lots.
- Stability: 12-month 2–8 °C projected, 1-month RT in-use coverage; no potency loss after 3 freeze/thaw cycles.
- CMC outcome: Agency feedback accepted control strategy; dossier advanced without major queries—exactly what you want from an Albumin Fusion Protein CDMO partnership.
Why Elise Biopharma for Albumin-Fusion?
- Deep fusion engineering: linker selection, domain orientation, FcRn tuning, and biophysics guided by potency vs. exposure trade-offs; dozens of fusion programs taken from concept to PPQ.
- QbD-backed process: rigorous DoE, well-characterized PARs, and scale-down models that actually predict full-scale behavior.
- Scalable infrastructure: mg-to-multi-kg, with harmonized DS→DP handoffs (sterile filtration, container-closure, in-use stability).
- Integrated regulatory authorship: comparator strategy, justification memos, and reviewer-friendly visuals; we write to be read.
- Program management: Gantt you can trust, risk burndown reviews, and decision-ready dashboards.
If you’re seeking an Albumin Fusion Protein CDMO that treats CMC as a product—not paperwork—Elise Biopharma is built to carry you from construct to approval with fewer surprises and shorter review cycles.
Next Steps
Ready to extend the half‑life of your therapeutic payload with albumin fusion?
Email our team at: info@elisebiopharma.com
Partner with Elise Biopharma to create purpose‑built fusion biologics that deliver lasting efficacy and improved patient compliance.
Check out our Fc-Fusion & Bispecific page below…